Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib maintenance after ASCT in multiple myeloma
jRCT2080222724Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival (PFS). Started Jan 2015; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222724.